| Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, ... New England Journal of Medicine 381 (17), 1632-1643, 2019 | 1273 | 2019 |
| Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial SB Kang, JW Park, SY Jeong, BH Nam, HS Choi, DW Kim, SB Lim, ... The lancet oncology 11 (7), 637-645, 2010 | 1234 | 2010 |
| Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy … YS Hong, BH Nam, K Kim, JE Kim, SJ Park, YS Park, JO Park, SY Kim, ... The lancet oncology 15 (11), 1245-1253, 2014 | 429 | 2014 |
| Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E–mutant metastatic colorectal cancer: updated survival results and subgroup analyses from … J Tabernero, A Grothey, E Van Cutsem, R Yaeger, H Wasan, T Yoshino, ... Journal of Clinical Oncology 39 (4), 273, 2021 | 349 | 2021 |
| Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers SB Lim, HS Choi, SY Jeong, DY Kim, KH Jung, YS Hong, HJ Chang, ... Annals of surgery 248 (2), 243-251, 2008 | 243 | 2008 |
| S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial YS Hong, YS Park, HY Lim, J Lee, TW Kim, K Kim, SY Kim, JY Baek, ... The lancet oncology 13 (11), 1125-1132, 2012 | 158 | 2012 |
| Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma J Kim, C Fox, S Peng, M Pusung, E Pectasides, E Matthee, YS Hong, ... The Journal of clinical investigation 124 (12), 5145-5158, 2014 | 128 | 2014 |
| Oxaliplatin-based adjuvant chemotherapy for rectal cancer after preoperative chemoradiotherapy (ADORE): long-term results of an open-label, multicentre, phase 2, randomised … YS Hong, SY Kim, JS Lee, BH Nam, K Kim, JE Kim, YS Park, JO Park, ... | 127 | 2019 |
| Influence of preoperative chemoradiotherapy on the number of lymph nodes retrieved in rectal cancer YH Ha, SY Jeong, SB Lim, HS Choi, YS Hong, HJ Chang, DY Kim, ... Annals of surgery 252 (2), 336-340, 2010 | 125 | 2010 |
| Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer JH Joo, J Park, JC Kim, CS Yu, SB Lim, IJ Park, TW Kim, YS Hong, K Kim, ... International Journal of Radiation Oncology* Biology* Physics 99 (4), 876-883, 2017 | 111 | 2017 |
| Carcinoembryonic antigen as a predictor of pathologic response and a prognostic factor in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy … JW Park, SB Lim, DY Kim, KH Jung, YS Hong, HJ Chang, HS Choi, ... International Journal of Radiation Oncology* Biology* Physics 74 (3), 810-817, 2009 | 103 | 2009 |
| Pathologic nodal classification is the most discriminating prognostic factor for disease-free survival in rectal cancer patients treated with preoperative chemoradiotherapy and … TH Kim, HJ Chang, DY Kim, KH Jung, YS Hong, SY Kim, JW Park, JH Oh, ... International Journal of Radiation Oncology* Biology* Physics 77 (4), 1158-1165, 2010 | 101 | 2010 |
| Tumor volume reduction rate measured by magnetic resonance volumetry correlated with pathologic tumor response of preoperative chemoradiotherapy for rectal cancer SG Yeo, DY Kim, TH Kim, KH Jung, YS Hong, HJ Chang, JW Park, SB Lim, ... International Journal of Radiation Oncology* Biology* Physics 78 (1), 164-171, 2010 | 100 | 2010 |
| Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study J Lee, KH Jung, YS Park, JB Ahn, SJ Shin, SA Im, DY Oh, DB Shin, ... Cancer chemotherapy and pharmacology 64, 657-663, 2009 | 93 | 2009 |
| Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5‐fluorouracil resistance YK Shin, BC Yoo, YS Hong, HJ Chang, KH Jung, SY Jeong, JG Park Electrophoresis 30 (12), 2182-2192, 2009 | 84 | 2009 |
| ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma I Yen, F Shanahan, J Lee, YS Hong, SJ Shin, AR Moore, J Sudhamsu, ... Nature 594 (7863), 418-423, 2021 | 81 | 2021 |
| Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study SY Kim, YS Hong, DY Kim, TW Kim, JH Kim, SA Im, KS Lee, T Yun, ... International Journal of Radiation Oncology* Biology* Physics 81 (3), 677-683, 2011 | 80 | 2011 |
| Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer YS Hong, J Lee, SC Lee, IG Hwang, SH Choi, JS Heo, JO Park, YS Park, ... Cancer chemotherapy and pharmacology 60, 321-328, 2007 | 79 | 2007 |
| A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis JC Jo, YS Hong, KP Kim, JL Lee, J Lee, YS Park, SY Kim, JS Ryu, JS Lee, ... Investigational new drugs 32, 369-376, 2014 | 75 | 2014 |
| Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1 YS Hong, SW Hong, SM Kim, DH Jin, JS Shin, DH Yoon, KP Kim, JL Lee, ... International journal of oncology 41 (1), 76-82, 2012 | 74 | 2012 |
